Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic human umbilical cord-derived mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intramuscular, Intrathecal, Intralesional, Intra-arterial, Implant
01
Overview
Allogeneic human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) are a population of multipotent stromal cells isolated from the Wharton's jelly of the human umbilical cord. These cells are characterized by their ability to differentiate into various cell lineages (osteoblasts, chondrocytes, adipocytes) and their potent immunomodulatory and regenerative properties. hUC-MSCs function primarily through paracrine mechanisms, secreting a diverse array of cytokines, chemokines, and growth factors—such as VEGF, HGF, and TGF-β—that promote angiogenesis, inhibit apoptosis, and suppress inflammatory immune responses. Due to their low immunogenicity (low MHC class I and lack of MHC class II expression), they are suitable for allogeneic transplantation without the need for intensive immunosuppression. They are being extensively investigated for treating autoimmune disorders, inflammatory conditions, and tissue injuries, often in combination with biomimetic scaffolds to enhance engraftment and local therapeutic effects.
- Other names
- human umbilical cord mesenchymal stem cellsWharton's jelly-derived mesenchymal stem cellsUC-MSCsumbilical cord-derived mesenchymal stem cells
Beyond the preview
Go deeper on allogeneic human umbilical cord-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic human umbilical cord-derived mesenchymal stem cells.